Interleukin-6 release in response to Coronavirus 19

Diaclone - Excellence in Immunoassay DevelopmentCoronavirus 19 is known to infect the respiratory tract and cause mild or highly acute respiratory syndrome. A consequence of this is the release of pro-inflammatory cytokines, including interleukin (IL)-1β and IL-6 (1). This hyperinflammatory response is thought to be the 2nd highest cause of death in COVID-19 cases (2), so understanding this response will be critical in understanding the disease.

Suppression of pro-inflammatory IL-6 has been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Indeed, a trial in China has already been approved to test tocilizumab (a IL-6 receptor blockade, licensed for cytokine release syndrome) for patients with COVID-19 pneumonia and elevated IL-6 (3).

To aid in COVID-19 research, Diaclone offer a large range of products for the quantification of human IL-6 and other human cytokines.

Diaclone’s Human IL-6 range includes:

Human IL-6 ELISA pair:

Diaclone also offer many other human cytokine antibodies and immunoassays such as TNF-alpha, IFN-gamma, IL-1-beta, IL-2, IL-7, and many more.

View all Diaclone Cytokine Products

View all Caltag Medsystems Coronavirus (COVID-19) Research Tools

Caltag Medsystems are the UK distributor for Diaclone. During the COVID-19 both us and Diaclone aim to continue to provide research tools to our customers. For more information on the product, or for an update on any business restrictions due to Coronavirus-19, please contact us.


  1. Conti et al. (2020) Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 14;34(2). pii: 1. doi: 10.23812/CONTI-E
  2. Ruan et al. Q, (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. (published online March 3.) DOI:10.1007/s00134-020-05991-x
  3. Chinese Clinical Trial Registry A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). Date: Feb 13, 2020, Date accessed: March 6, 2020

Related COVID-19 Posts

Interleukin-6 release in response to Coronavirus 19
Tagged on: